250 related articles for article (PubMed ID: 2829381)
21. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
Klin Wochenschr; 1988; 66 Suppl 12():102-8. PubMed ID: 3126339
[TBL] [Abstract][Full Text] [Related]
22. Fibrin-specific thrombolytic agents.
Collen D
Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
[TBL] [Abstract][Full Text] [Related]
23. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
Lu HR; Lijnen HR; Stassen JM; Collen D
Blood; 1991 Jul; 78(1):125-31. PubMed ID: 1906351
[TBL] [Abstract][Full Text] [Related]
24. Additive fibrinolysis by recombinant tissue-type plasminogen activator (r-t-PA) and recombinant single-chain urokinase type plasminogen activator (r-scu-PA) in rabbit pulmonary thrombosis.
Schneider J; Friderichs E; Günzler WA; Flohé L
Thromb Res; 1989 Oct; 56(1):59-65. PubMed ID: 2512686
[TBL] [Abstract][Full Text] [Related]
25. [Successful lysis of a septic thrombosis of the superior vena cava using recombinant tissue-plasminogen activator].
Schranz D; Haugwitz D; Zimmer B; Schumacher R
Klin Padiatr; 1991; 203(5):363-5. PubMed ID: 1942943
[TBL] [Abstract][Full Text] [Related]
26. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
27. Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.
Gurewich V
Semin Thromb Hemost; 1989 Apr; 15(2):123-8. PubMed ID: 2501871
[No Abstract] [Full Text] [Related]
28. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
Sugimoto K; Hofmann LV; Razavi MK; Kee ST; Sze DY; Dake MD; Semba CP
J Vasc Surg; 2003 Mar; 37(3):512-7. PubMed ID: 12618684
[TBL] [Abstract][Full Text] [Related]
29. [Development of new thrombolytic substances].
Zeymer U; Neuhaus KL
Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
[TBL] [Abstract][Full Text] [Related]
30. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
Ziskind AA; Gold HK; Yasuda T; Kanke M; Guerrero JL; Fallon JT; Saito T; Collen D
Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
[TBL] [Abstract][Full Text] [Related]
31. Additional myocardial salvage by coadministration of the epoprostenol analog taprostene to recombinant single-chain urokinase-type plasminogen activator in a canine coronary thrombosis model.
Groves R; Schneider J; Friderichs E; Giertz H; Flohé L
Arzneimittelforschung; 1989 Apr; 39(4):534-8. PubMed ID: 2665759
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
33. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
Collen D; Stassen JM; Blaber M; Winkler M; Verstraete M
Thromb Haemost; 1984 Aug; 52(1):27-30. PubMed ID: 6541817
[TBL] [Abstract][Full Text] [Related]
34. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E
Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856
[No Abstract] [Full Text] [Related]
35. Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin.
Eriksson E; Wollter IM; Christenson B; Stigendal L; Risberg B
Thromb Haemost; 1988 Apr; 59(2):284-8. PubMed ID: 2838926
[TBL] [Abstract][Full Text] [Related]
36. Fibrin specific thrombolysis by two-chain urokinase-type plasminogen activator cleaved after arginine 156 by thrombin.
Abercrombie DM; Buchinski B; Salvato KA; Vovis GF; Stump DC; Broeze RJ
Thromb Haemost; 1990 Nov; 64(3):426-32. PubMed ID: 2128973
[TBL] [Abstract][Full Text] [Related]
37. Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
Spriggs DJ; Stassen JM; Hashimoto Y; Collen D
Blood; 1989 Apr; 73(5):1207-12. PubMed ID: 2495034
[TBL] [Abstract][Full Text] [Related]
38. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
[TBL] [Abstract][Full Text] [Related]
39. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
Collen D; Stassen JM; Marafino BJ; Builder S; De Cock F; Ogez J; Tajiri D; Pennica D; Bennett WF; Salwa J
J Pharmacol Exp Ther; 1984 Oct; 231(1):146-52. PubMed ID: 6541693
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of single chain forms of urokinase-type plasminogen activator.
Stump DC; Kieckens L; De Cock F; Collen D
J Pharmacol Exp Ther; 1987 Jul; 242(1):245-50. PubMed ID: 3612530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
